The Medical Advisor

Weight-loss medications such as Ozempic, Wegovy, Mounjaro, and Zepbound have reshaped obesity treatment. By 2026, millions of people are using GLP-1 receptor agonists or dual GLP-1/GIP drugs to lose weight, improve metabolic health, and reduce cardiometabolic risk. But there’s a hidden issue clinicians are increasingly discussing: Up to 30–40% of the weight lost on GLP-1 therapy can come from lean muscle mass. If that muscle loss isn’t addressed, patients may reach their goal weight but end up with slower metabolism, reduced strength, and higher long-term weight regain risk. This is sometimes called “GLP-1 muscle drain.” The solution isn’t stopping the medication. Instead, experts are increasingly recommending a Protein-Sparing Protocol —a structured approach designed to preserve muscle while maximizing fat loss. Below is the practical, evidence-informed roadmap. 1. The Problem: The “Muscle Drain” Phenomenon GLP-1 medications work primarily by: Slowing gastric emptying Increasing satie...

Peptides are short chains of amino acids (typically 2–50 residues) that function as high-specificity signaling molecules across endocrine, neurologic, immune, metabolic, and regenerative systems. In modern clinical practice, peptide therapeutics range from life-saving hormones (e.g., Insulin ) to cardiometabolic agents (e.g., Glucagon-like peptide-1 receptor agonists) and investigational regenerative fragments such as TB-500 and KPV. This review provides a clinician-facing synthesis of: Mechanistic biology (receptor signaling, downstream pathways) Evidence grading (A–D framework) Approved indications and outcome data Safety, oncology considerations, and medicolegal issues Practical clinical decision-making frameworks Why Peptides Matter in Clinical Medicine Peptides occupy a unique therapeutic niche: High receptor specificity → lower off-target effects (relative to many s...

Introduction In recent years, GLP-1 receptor agonists have emerged as one of the most important breakthroughs in modern metabolic medicine. Originally developed to treat type 2 diabetes, these medications are now widely used for weight loss, cardiovascular risk reduction, and metabolic disease management . Drugs such as Ozempic, Wegovy, and Mounjaro have rapidly gained global attention for their ability to produce significant and sustained weight loss while improving multiple cardiometabolic risk factors. GLP-1 (glucagon-like peptide-1) is a natural hormone released from the gut after eating. It plays a key role in regulating blood sugar, appetite, and digestion. By mimicking or enhancing this hormone’s activity, GLP-1 drugs help reduce hunger, slow gastric emptying, improve insulin secretion, and support healthier glucose control. Over the past decade, large randomized clinical trials have demonstrated that these medications can lead to 10–20% reductions in body weight , alongside me...

Semaglutide, known by the brand names Ozempic, Wegovy, Rybelsus and others, is the latest weight-loss craze to hit Hollywood and beyond. The prescription drug, which is administered via a weekly injection, is intended to treat Type 2 diabetes, but it’s widely used off-label for weight loss. They all belong to the same medication class — glucagon-like peptide-1 (GLP-1) agonists ( GLP-1 receptor agonists ).  GLP-1 agonists work by triggering insulin release, blocking sugar production in your liver, and making you feel full. But with all of these brands out there, how do you decide which is right for you? Let’s get to know some of the differences between these major GLP-1 agonist drugs. A 2021 study funded by Novo Nordisk, the drug’s maker, found using semaglutide once a week led to a 14.9% reduction in body weight among adults with obesity. There’s been such a rush on the drugs that the U.S. Food and Drug Administration lists both Ozempic and Wegovy a...

Abstract Background: Lung cancer, particularly advanced or metastatic non–small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), remains a leading cause of cancer mortality worldwide. Conventional therapies such as targeted agents, immunotherapy, and chemotherapy offer survival benefits but often yield limited results in treatment-resistant or late-stage disease. Repurposing widely available antiparasitic drugs — fenbendazole , ivermectin , and mebendazole — has garnered attention in integrative oncology communities due to reported anticancer effects in preclinical studies and emerging anecdotal clinical observations. Objective: To summarize a compilation of real-world case reports describing the use of fenbendazole, ivermectin, and mebendazole in lung cancer patients, highlighting reported clinical outcomes and therapeutic contexts. Methods: This review synthesizes case narratives and outcome descriptions publicly shared through online platforms, including clinicians...